Diet induced modifications of fatty-acid composition in mealworm larvae (Tenebrio molitor)

The diet of Western human societies is characterized by an excess of saturated fatty acids (FAs) and a high concentration of ω-6 relative to ω-3 polyunsaturated FA (PUFA). These unbalanced diets are suspected to trigger diseases and disorders. To alleviate this public health concern, the production of healthier meat with more PUFAs of higher ω-3 concentration could potentially be achieved by modifying livestock diets. The high nutritional value and limited breeding costs of edible insects have brought insect feed into the discussion as a promising fat source for animal and human diets. In this study, we sought to increase the amount of ω-3 PUFAs in mealworm (Tenebrio molitor) larvae. We investigated the effects of diets varying in ω-3/ω-6 ratio and FA concentration but similar in PUFA proportion on larva FA composition. Mealworm larvae showed significant plasticity in lipid composition. High dietary ω-3/ω-6 ratios induced an increase in the proportion of ω-3 and a decrease in ω-6, which resulted in higher larval ω-3/ω-6 ratios, but also in higher larval PUFA proportion. Increasing FA concentrations in larva diets also favored the accumulation of PUFAs to the detriment of monounsaturated and saturated FAs. Providing ω-3-rich seeds to mealworm larvae could allow the production of economical animal fat with healthier PUFA percentages (> 60%) and ω-3/ω-6 ratios (>0.5)

Cardiac monitoring during adjuvant trastuzumab therapy: Guideline adherence in clinical practice

Cardiotoxicity is an important adverse effect of adjuvant breast cancer treatment with trastuzumab and three monthly left ventricular ejection fraction (LVEF) monitoring is considered mandatory. The purpose of this study was to gain insight into LVEF monitoring during adjuvant trastuzumab treatment in clinical practice. In a multicenter retrospective study encompassing 328 patients, of which 171 patients were actually treated with trastuzumab, we analyzed the frequency and mode of LVEF monitoring and compared it with LVEF monitoring guidelines. The results indicated poor guideline adherence. In 9% of patients trastuzumab was started in spite of a low LVEF ( <55%). In 24% of patients no valid baseline LVEF value was available. LVEF measurements during treatment at three, six and 12 months were only performed in, respectively, 53%, 40% and 30% of patients. A significant proportion of patients are treated with trastuzumab, while LVEF monitoring is not adequately performed. More attention should be paid to the implementation of (cardiac assessment) guidelines in clinical practic